| 摘要 |
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to medicine, namely to therapy, and may be used for treating the disorders related to CXCL13 activity in an animal's cell, tissue, organ or body wherein the disorders represent chronic obstructive pulmonary disease (COPD) or systemic lupus erythematosus. That is ensured by introducing a CXCL13 antagonist into the animal's cell, tissue, organ or body in an amount effective for CXCL13 activity inhibition together with a TNF antagonist in an amount effective for TNF activity inhibition in said animal's cell, tissue, organ or body. ^ EFFECT: group of inventions provides treating chronic obstructive pulmonary disease and systemic lupus erythematosus due to the combined use of the CXCL13 and TNF specific monoclonal antibodies that leads to decreased CD4 expressing B-cell infiltration, and also reduced glomerulonephritis related urinary protein in an animal with symptoms of systemic lupus erythematosus. ^ 19 cl, 8 dwg, 3 tbl, 4 ex |
